GABA (gamma-Aminobutyric Acid) for Anxiety
Early human trials suggest oral GABA may modestly ease anxiety, but the evidence is limited and low-quality, so it should not be treated as a proven anxiety treatment. No regulator or major clinic endorses it for this use.
Why this grade7-layer evidence engine
This earns a preliminary (Tier B) grade because the supporting human data is thin and mixed. A 2020 systematic review (PMID 33041752, 14 studies) found only limited, heterogeneous signals for stress and anxiety—some EEG alpha-wave and autonomic changes—but the trials were too small and varied to pool into a meta-analysis.
Two small randomized trials hint at benefit: a 2025 open-label RCT in 168 surgical patients (PMID 40026748) compared GABA against L-theanine (not placebo) for pre-operative anxiety relief, so it shows GABA performing comparably to another supplement rather than isolating a GABA-specific benefit, and a 2024 double-blind RCT in 30 women (PMID 38321713) showed improved DASS-21 depression and mood scores over 13 weeks (its primary outcome was depression, not anxiety). Both are small, short, and one is unblinded, so they raise the grade only modestly.
Caution is warranted: it is disputed whether oral GABA even crosses the blood-brain barrier, and several key studies have undisclosed or industry-linked funding. The US FDA lists GABA only as a flavoring agent, not an approved food ingredient, and no major health authority or clinic endorses it for anxiety—so it remains a possible aid, not a substitute for established care.
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditable▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.58
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status